Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.55 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.54 |
| ▸ | PRKD1 | Q15139 | 8/20 | 0.48 |
| ▸ | PRKD2 | Q9BZL6 | 7/20 | 0.48 |
| ▸ | DPP4 | P27487 | 3/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.46 |
| ▸ | PDE4A | P27815 | 2/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.46 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30818737 | 0.80 | PIK3CB (0.49) | HRH4PRKD1PRKD2DPP4 | |
| SCHEMBL1774962 | 0.78 | HRH4 (0.67) | KDRHRH4DPP4CHRM3PDE4A | |
| SCHEMBL4789831 | 0.77 | PRKD1 (0.48) | HRH4PRKD1PRKD2DPP4CHRM3 | |
| SCHEMBL1775475 | 0.77 | PRKD1 (0.48) | HRH4PRKD1PRKD2DPP4CHRM3 | |
| SCHEMBL30818649 | 0.77 | HRH4 (0.49) | HRH4DPP4 | |
| SCHEMBL1775075 | 0.77 | HRH4 (0.62) | KDRHRH4 | |
| SCHEMBL30818620 | 0.76 | IRAK4 (0.47) | HRH4 | |
| SCHEMBL30819046 | 0.76 | HRH4 (0.42) | KDRHRH4PRKD1PRKD2DPP4 | |
| SCHEMBL1774625 | 0.75 | HRH4 (0.93) | KDRHRH4 | |
| SCHEMBL17623265 | 0.75 | HRH4 (0.63) | KDRHRH4ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966162-B1 | PYRIMIDINE DERIVATIVES | ZIARCO PHARMA LTD (GB) | 2017-03-15 | — | — | EP | disclosed |
| US-7943628-B2 | Pyrimidine derivatives | PFIZER LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| EP-1966162-A2 | PYRIMIDINE DERIVATIVES | Pfizer Limited (GB) | 2008-09-10 | — | — | EP | disclosed |
| US-20070185075-A1 | Pyrimidine derivatives | PFIZER LIMITED | 2007-08-09 | — | — | US | disclosed |
| WO-2007072163-A2 | PYRIMIDINE DERIVATIVES | PFIZER LIMITED (GB) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185075-A1 | Pyrimidine derivatives | TYMS, DPYD, TYMP | KDR 585/4885HRH4 184/4885PRKD1 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.